D-TACE + lenvatinib + tislelizumab

D-TACE + lenvatinib + tislelizumab is an investigational combination regimen being evaluated for the treatment of advanced unresectable hepatocellular carcinoma (HCC). The regimen integrates three distinct therapeutic modalities: Drug-eluting Bead Transarterial Chemoembolization (D-TACE) using pirarubicin-loaded CalliSpheres (100-300 µm), the oral multi-kinase inhibitor lenvatinib, and the intravenous anti-PD-1 monoclonal antibody tislelizumab. D-TACE provides a dual effect by delivering high-dose chemotherapy (pirarubicin) directly to the tumor while simultaneously inducing ischemia through embolization. Lenvatinib targets multiple tyrosine kinases, including VEGFR1-3 and FGFR1-4, to inhibit angiogenesis and lymphangiogenesis. Tislelizumab is a humanized IgG4 monoclonal antibody that binds to PD-1, preventing its interaction with PD-L1 and PD-L2 to enhance the immune system's ability to detect and destroy cancer cells. This triple-modality approach is currently being compared against HAIC-based combination therapies in clinical trials led by investigator Wen Li.

Brand names

CalliSpheresLenvimaTevimbra

Other names

D-TACE-Wen Li-hepatocellular carcinomaD-TACE plus lenvatinib and tislelizumabD-TACE-L-T